Literature DB >> 30018042

Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth.

Ilenia Pacella1, Ilenia Cammarata1, Chiara Focaccetti1, Stefano Miacci1, Alessandro Gulino2, Claudio Tripodo2, Micol Ravà3, Vincenzo Barnaba4,5,6, Silvia Piconese1,5.   

Abstract

The Wnt/β-catenin pathway regulates T-cell functions, including the repression of effector functions to the advantage of memory development via Tcf1. In a companion study, we demonstrate that, in human cancers, Wnt3a/β-catenin signaling maintains tumor-infiltrating T cells in a partially exhausted status. Here, we have investigated the effects of Wnt3a neutralization in vivo in a mouse tumor model. Abundant Wnt3a was released, mostly by stromal cells, in the tumor microenvironment. We tested whether Wnt3a neutralization in vivo could rescue the effector capacity of tumor-infiltrating T cells, by administering an antibody to Wnt3a to tumor-bearing mice. This therapy restrained tumor growth and favored the expansion of tumor antigen-specific CD8+ effector memory T cells with increased expression of Tbet and IFNγ and reduced expression of Tcf1. However, the effect was not attributable to the interruption of T-cell-intrinsic β-catenin signaling, because Wnt3a/β-catenin activation correlated with enhanced, not reduced, T-cell effector functions both ex vivo and in vitro Adoptively transferred CD8+ T cells, not directly exposed to the anti-Wnt3a antibody but infiltrating previously Wnt3a-neutralized tumors, also showed improved functions. The rescue of T-cell response was thus secondary to T-cell-extrinsic changes that likely involved dendritic cells. Indeed, tumor-derived Wnt3a strongly suppressed dendritic cell maturation in vitro, and anti-Wnt3a treatment rescued dendritic cell activities in vivo Our results clarify the function of the Wnt3a/β-catenin pathway in antitumor effector T cells and suggest that Wnt3a neutralization might be a promising immunotherapy for rescuing dendritic cell activities. Cancer Immunol Res; 6(8); 953-64. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30018042     DOI: 10.1158/2326-6066.CIR-17-0713

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  10 in total

1.  Co-expressing LRP6 With Anti-CD19 CAR-T Cells for Improved Therapeutic Effect Against B-ALL.

Authors:  Ping He; Zhongqiu Tan; Zhongheng Wei; Cheng-Liang Wan; Shan-Shan Yang
Journal:  Front Oncol       Date:  2020-09-15       Impact factor: 6.244

2.  Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma.

Authors:  Dimitra Kerdidani; Panagiotis Chouvardas; Ares Rocanin Arjo; Ioanna Giopanou; Giannoula Ntaliarda; Yu Amanda Guo; Mary Tsikitis; Georgios Kazamias; Konstantinos Potaris; Georgios T Stathopoulos; Spyros Zakynthinos; Ioannis Kalomenidis; Vassili Soumelis; George Kollias; Maria Tsoumakidou
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919

Review 3.  Wnt Signaling Cascade in Dendritic Cells and Regulation of Anti-tumor Immunity.

Authors:  Amol Suryawanshi; Mohamed S Hussein; Puttur D Prasad; Santhakumar Manicassamy
Journal:  Front Immunol       Date:  2020-02-17       Impact factor: 7.561

4.  Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy.

Authors:  Nicola Principe; Joel Kidman; Siting Goh; Caitlin M Tilsed; Scott A Fisher; Vanessa S Fear; Catherine A Forbes; Rachael M Zemek; Abha Chopra; Mark Watson; Ian M Dick; Louis Boon; Robert A Holt; Richard A Lake; Anna K Nowak; Willem Joost Lesterhuis; Alison M McDonnell; Jonathan Chee
Journal:  Front Immunol       Date:  2020-11-12       Impact factor: 7.561

Review 5.  Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities.

Authors:  Jiaqi Liu; Qing Xiao; Jiani Xiao; Chenxi Niu; Yuanyuan Li; Xiaojun Zhang; Zhengwei Zhou; Guang Shu; Gang Yin
Journal:  Signal Transduct Target Ther       Date:  2022-01-03

6.  Wnt5A signaling supports antigen processing and CD8 T cell activation.

Authors:  Tresa Rani Sarraf; Malini Sen
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

7.  Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells.

Authors:  Dandan Fan; Qi Yue; Jian Chen; Cong Wang; Ruilin Yu; Ziyi Jin; Shujie Yin; Qinyue Wang; Luo Chen; Xueling Liao; Chengyuan Peng; Jianpin Zhang; Zhonglian Cao; Ying Mao; Ruimin Huang; Liang Chen; Cong Li
Journal:  Oncoimmunology       Date:  2021-06-06       Impact factor: 8.110

Review 8.  T Cell Memory in Infection, Cancer, and Autoimmunity.

Authors:  Vincenzo Barnaba
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

9.  Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells.

Authors:  Monica Benvenuto; Sara Ciuffa; Chiara Focaccetti; Diego Sbardella; Sara Fazi; Manuel Scimeca; Grazia Raffaella Tundo; Giovanni Barillari; Maria Segni; Elena Bonanno; Vittorio Manzari; Andrea Modesti; Laura Masuelli; Massimo Coletta; Roberto Bei
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

10.  β-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer.

Authors:  Caihong Wang; Jingjing Yan; Pan Yin; Liming Gui; Lu Ji; Bin Ma; Wei-Qiang Gao
Journal:  Oncoimmunology       Date:  2020-08-31       Impact factor: 7.723

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.